Abstract: Objective To investigate the clinical efficacy of the short-term intravenous glucocorticoid after primary total knee arthroplasty and to evaluate the security of the patients. Methods From March 2016 to March 2018,348 cases (496 knees) who met the inclusion criteria had received primary total knee arthroplasty (TKA) in our hospital. All of the patients were divided into two groups according to whether glucocorticoid was used after operation-regular group (186 patients,266 knees) and hormone group (162 cases,230 knees). Observation indexes include:visual analogue scale (VAS) and range of motion 1 to 7days after the operation,hospital for special surgery scores at the first week after the operation and the postoperative complications rate,include nausea,vomiting,wound healing and joint infection. Results The VAS and range of motion (ROM) after surgery of the Hormone group was significantly better than the normal group,also relate to the HSS score,with significant difference between these two groups. Furthermore,the incidence of nausea and vomiting in the hormone group was significantly lower than that in the normal group,and there was no significant difference in the incidence of wound healing and infection. Conclusion Short-term intravenous application of glucocorticoid hormones can significantly reduce postoperative pain patients,reduce postoperative nausea and vomiting,promote the knee function recovery,at the same time does not increase complications such as poor wound healing,infection of joint after replacement.

Key words: arthroplasty, replacement, knee, glucocorticoids